Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question-Reference-Cited by-同舟云学术

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question

Published:2022-08-20 Issue:3 Volume:78 Page:441-445
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Caramella Irene,Dalla Volta Alberto,Bergamini Marco,Cosentini Deborah,Valcamonico Francesca,Berruti Alfredo^ORCID

Abstract

Abstract Purpose Whether or not androgen receptor (AR) axis could still be targetable in castration resistant prostate cancer (CRPC) patients with disease progression to next generation hormonal agents (NGHAs) is a controversial issue. Results Serum testosterone in CRPC patients has a positive prognostic role and increasing testosterone levels after androgen deprivation therapy (ADT) withdrawal or testosterone supplementation, as part of a bipolar androgen therapy (BAT) strategy, has been shown to potentially restore sensitivity to previous lines of NGHAs. Conclusion These data suggest that maintenance of ADT in CRPC patients receiving further lines of treatment, as recommended by current international guidelines, could be questionable. Conversely, testosterone supplementation aimed to re-sensitize CRPC to further hormonal manipulation is a strategy worth to be explored in future clinical trials.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-022-03166-w.pdf

Reference27 articles.

1. A. Berruti, A. Dalla Volta, Resistance to hormonal therapy in prostate cancer. Handb. Exp. Pharm. 249, 181–194 (2018). https://doi.org/10.1007/164_2017_21

2. O. Caffo, U. De Giorgi, L. Fratino et al. clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian Multicentre Study. Eur. Urol. 68, 147–153 (2015). https://doi.org/10.1016/j.eururo.2014.10.014

3. R. de Wit, J. de Bono, C.N. Sternberg et al. Cabazitaxel versus Abiraterone or Enzalutamide in metastatic prostate cancer. N. Engl. J. Med 381(26), 2506–2518 (2019). https://doi.org/10.1056/NEJMoa1911206

4. P. Cornford, R.C.N. van den Bergh, E. Briers et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of relapsing and metastatic prostate cancer. Eur. Urol. S0302-2838(20), 30773–30779 (2020)

5. C.D. Taylor, P. Elson, D.L. Trump, Importance of continued testicular suppression in hormone-refractory prostate cancer. J. Clin. Oncol. 11, 2167–2172 (1993)